Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01MH045436-02 | U.S. NIH Grant/Contract | View source | |
| DSIR 83-ATAS | |||
| R01MH045436 | U.S. NIH Grant/Contract | View source | |
| R01MH045404 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Mental Health (NIMH) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will compare the short- and long-term effectiveness of two common therapies in improving serotonin reuptake inhibitor treatment in people with obsessive-compulsive disorder.
Obsessive-compulsive disorder (OCD) is a common psychiatric illness. People with OCD experience unwelcome thoughts, known as obsessions, and feel compelled to perform repetitive behaviors, or compulsions. Impairment due to OCD symptoms ranges from mild to severe, and sometimes can be disabling. The only medications proven effective for OCD are serotonin reuptake inhibitors (SRIs), but even with SRI treatment, most patients continue to experience significant OCD symptoms, impaired functioning, and diminished quality of life. Cognitive-behavioral therapy (CBT), a talking therapy that focuses on altering a person's thoughts and behaviors, and the medication risperidone have both been commonly used for augmenting SRI treatment for OCD. This study will compare the short- and long-term effectiveness of exposure and ritual prevention (EX/RP), a type of CBT, and risperidone in augmenting SRI treatment in people with OCD.
Participants in this double-blind study will be randomly assigned to receive EX/RP, risperidone, or placebo in conjunction with their regular SRI medication. All participants will remain on their regular SRI at a stable dose. During the first 2 months of the study, participants assigned to EX/RP will attend therapy sessions twice per week. In EX/RP, participants will be exposed to feared objects or ideas, and will be encouraged not to carry out a compulsive response. Participants assigned to risperidone or placebo will meet with a psychiatrist once every 1 to 2 weeks. At the end of 8 weeks, all participants' OCD symptom severity will be assessed. During this time, participants who have responded to treatment will continue receiving the same treatment for an additional 24 weeks. Participants assigned to EX/RP will meet with a therapist no more than 15 times total, and participants receiving risperidone or placebo will meet with a psychiatrist once every 4 weeks. Outcomes will be reassessed at study completion.
Ortho McNeil Janssen Scientific Affairs, LLC are providing medication and placebos for this study.
For information on a related study, please follow this link:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Active Comparator | Participants will receive treatment with risperidone |
|
| 2 | Active Comparator | Participants will receive exposure and ritual prevention therapy (EX/RP) |
|
| 3 | Placebo Comparator | Participants will receive treatment with the placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Risperidone | Drug | Dosage of 0.5 mg to 4.0 mg per day as tolerated |
|
| Measure | Description | Time Frame |
|---|---|---|
| Score on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) | Y-BOCS ranges from 0-40, with 0 meaning no symptoms and higher numbers meaning greater symptom severity | Week 0 and Week 8 |
| Measure | Description | Time Frame |
|---|---|---|
| Social Adjustment Scale-SR | SAS-SR yields a mean score between 1 and 5; the higher the score, the more severe the social adjustment problems | Week 0 and Week 8 |
| Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Blair Simpson, MD, PhD | New York State Psychiatric Institute | Principal Investigator |
| Edna Foa, PhD | University of Pennsylvania | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| New York State Psychiatric Institute | New York | New York | 10032 | United States | ||
| University of Pennsylvania Center for the Treatment and Study of Anxiety |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 24026523 | Result | Simpson HB, Foa EB, Liebowitz MR, Huppert JD, Cahill S, Maher MJ, McLean CP, Bender J Jr, Marcus SM, Williams MT, Weaver J, Vermes D, Van Meter PE, Rodriguez CI, Powers M, Pinto A, Imms P, Hahn CG, Campeas R. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiatry. 2013 Nov;70(11):1190-9. doi: 10.1001/jamapsychiatry.2013.1932. | |
| 26613263 | Derived |
| Label | URL |
|---|---|
| Click here for the Columbia University Obsessive-Compulsive Disorder Research Clinic website | View source |
Not provided
Not provided
A randomized clinical trial (conducted January 2007-August 2012) at 2 academic outpatient research clinics that specialize in OCD and anxiety disorders. Patients (aged 18-70 years) were eligible if they had OCD of at least moderate severity despite a therapeutic SRI dose for at least 12 weeks prior to entry.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Treatment With Risperidone | Participants will receive treatment with risperidone Risperidone : Dosage of 0.5 mg to 4.0 mg per day as tolerated |
| FG001 | Treatment With Exposure/Response Prevention |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Exposure/ritual prevention therapy (EX/RP) | Behavioral | EX/RP is a form of cognitive behavioral therapy. Participants assigned to EX/RP will attend therapy sessions twice per week. In EX/RP, participants will be exposed to feared objects or ideas, and will be encouraged not to carry out a compulsive response. |
|
|
| Placebo | Drug | Placebo capsules will be identical in appearance to those of risperidone. |
|
|
QLESQ ranges from 14-70, with higher scores meaning more enjoyment and satisfaction with quality of life
| Week 0 and Week 8 |
| Hamilton Depression Rating Scale (Ham-D) | Ham-D ranges from 0=no symptoms to 52 with higher numbers indicating more severe depression | Week 0 and Week 8 |
| Brown Assessment of Beliefs (BABS) | Scale ranges from 0 to 24 where 0 is "beliefs are false" and 24 is "convinced beliefs = reality" | Week 0 and Week 8 |
| Philadelphia |
| Pennsylvania |
| 19104 |
| United States |
| McLean CP, Zandberg LJ, Van Meter PE, Carpenter JK, Simpson HB, Foa EB. Exposure and response prevention helps adults with obsessive-compulsive disorder who do not respond to pharmacological augmentation strategies. J Clin Psychiatry. 2015 Dec;76(12):1653-7. doi: 10.4088/JCP.14m09513. |
| 25375780 | Derived | Foa EB, Simpson HB, Rosenfield D, Liebowitz MR, Cahill SP, Huppert JD, Bender J Jr, McLean CP, Maher MJ, Campeas R, Hahn CG, Imms P, Pinto A, Powers MB, Rodriguez CI, Van Meter PE, Vermes D, Williams MT. Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder. J Clin Psychiatry. 2015 Apr;76(4):440-6. doi: 10.4088/JCP.14m09044. |
| 23945445 | Derived | Farris SG, McLean CP, Van Meter PE, Simpson HB, Foa EB. Treatment response, symptom remission, and wellness in obsessive-compulsive disorder. J Clin Psychiatry. 2013 Jul;74(7):685-90. doi: 10.4088/JCP.12m07789. |
| Click here for the University of Pennsylvania Center for the Treatment and Study of Anxiety website | View source |
| Click here to view the ClinicalTrials.gov record of this trial's parent study | View source |
Participants will receive exposure and response prevention therapy
Exposure/ritual prevention therapy (EX/RP) : EX/RP is a form of cognitive behavioral therapy. Participants assigned to EX/RP will attend therapy sessions twice per week. In EX/RP, participants will be exposed to feared objects or ideas, and will be encouraged not to carry out a compulsive response.
| FG002 | Treatment With Pill Placebo | Participants will receive treatment with the placebo Placebo : Placebo capsules will be identical in appearance to those of risperidone. |
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Treatment With Risperidone | Participants will receive treatment with risperidone Risperidone : Dosage of 0.5 mg to 4.0 mg per day as tolerated |
| BG001 | Treatment With Exposure/Response Prevention | Participants will receive exposure and response prevention therapy Exposure/ritual prevention therapy (EX/RP) : EX/RP is a form of cognitive behavioral therapy. Participants assigned to EX/RP will attend therapy sessions twice per week. In EX/RP, participants will be exposed to feared objects or ideas, and will be encouraged not to carry out a compulsive response. |
| BG002 | Treatment With Pill Placebo | Participants will receive treatment with the placebo Placebo : Placebo capsules will be identical in appearance to those of risperidone. |
| BG003 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Score on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) | Y-BOCS ranges from 0-40, with 0 meaning no symptoms and higher numbers meaning greater symptom severity | Posted | Mean | Standard Deviation | units on a scale | Week 0 and Week 8 |
|
|
| |||||||||||||||||||||||||||||||||
| Secondary | Social Adjustment Scale-SR | SAS-SR yields a mean score between 1 and 5; the higher the score, the more severe the social adjustment problems | Posted | Mean | Standard Deviation | units on a scale | Week 0 and Week 8 |
| |||||||||||||||||||||||||||||||||||
| Secondary | Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form | QLESQ ranges from 14-70, with higher scores meaning more enjoyment and satisfaction with quality of life | Posted | Mean | Standard Deviation | units on a scale | Week 0 and Week 8 |
| |||||||||||||||||||||||||||||||||||
| Secondary | Hamilton Depression Rating Scale (Ham-D) | Ham-D ranges from 0=no symptoms to 52 with higher numbers indicating more severe depression | Posted | Mean | Standard Deviation | units on a scale | Week 0 and Week 8 |
|
| ||||||||||||||||||||||||||||||||||
| Secondary | Brown Assessment of Beliefs (BABS) | Scale ranges from 0 to 24 where 0 is "beliefs are false" and 24 is "convinced beliefs = reality" | Posted | Mean | Standard Deviation | units on a scale | Week 0 and Week 8 |
|
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Treatment With Risperidone | Participants received treatment with risperidone Risperidone : Dosage of 0.5 mg to 4.0 mg per day as tolerated Mean Y-BOCS score measured at week 8 | 0 | 40 | 30 | 40 | ||
| EG001 | Treatment With Exposure/Response Prevention | Participants received exposure and response prevention therapy Exposure/ritual prevention therapy (EX/RP) : EX/RP is a form of cognitive behavioral therapy. Participants assigned to EX/RP will attend therapy sessions twice per week. In EX/RP, participants will be exposed to feared objects or ideas, and will be encouraged not to carry out a compulsive response. Mean Y-BOCS score measured at week 8 | 0 | 40 | 22 | 40 | ||
| EG002 | Treatment With Pill Placebo | Participants received treatment with the placebo Placebo : Placebo capsules will be identical in appearance to those of risperidone. Mean Y-BOCS score measured at week 8 | 0 | 20 | 13 | 20 |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Headache | Nervous system disorders | Systematic Assessment |
| ||
| Myalgia | Musculoskeletal and connective tissue disorders |
| |||
| Nausea | Gastrointestinal disorders |
| |||
| Sweating | General disorders |
| |||
| Photophobia | Eye disorders |
| |||
| Constipation | Gastrointestinal disorders |
| |||
| Lightheadedness | Nervous system disorders |
| |||
| Dry Mouth | Gastrointestinal disorders |
| |||
| Blurry Vision | Eye disorders |
| |||
| Decreased Libido | Reproductive system and breast disorders |
| |||
| Anorgasmia/Erectile Failure | Reproductive system and breast disorders |
| |||
| Impaired Coordination | Nervous system disorders |
| |||
| Fatigue | Nervous system disorders |
| |||
| Nervousness | Nervous system disorders |
| |||
| Insomnia | Nervous system disorders |
| |||
| Tremor | Nervous system disorders |
| |||
| Weight Gain | Gastrointestinal disorders |
| |||
| Weight Loss | Gastrointestinal disorders |
| |||
| Dermatitis | Skin and subcutaneous tissue disorders |
| |||
| Urinary Dysfunction | Renal and urinary disorders |
| |||
| Changes in breasts | Reproductive system and breast disorders |
| |||
| Increased thirst | Gastrointestinal disorders |
| |||
| Somnolence | Nervous system disorders |
| |||
| Extrapyramidal symptoms | Nervous system disorders |
|
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Helen Blair Simpson | New York State Psychiatric Institute | 646-774-7000 | kimeldo@nyspi.columbia.edu |
| ID | Term |
|---|---|
| D009771 | Obsessive-Compulsive Disorder |
| ID | Term |
|---|---|
| D001008 | Anxiety Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D018967 | Risperidone |
| ID | Term |
|---|---|
| D011744 | Pyrimidinones |
| D011743 | Pyrimidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
| Between 18 and 65 years |
|
| >=65 years |
|
| Male |
|
|
| Units | Counts |
|---|
| Participants |
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
| Participants |
|
|
| Participants |
|
|